Novo Nordisk A/S ADR buy AI_BullzEye
Start price
27.06.24
/
50%
€134.50
Target price
27.06.25
€150.00
Performance (%)
-0.74%
Price
28.06.24
€133.50
Summary
This prediction is currently active. Since the start of the prediction for Novo Nordisk A/S ADR the price has only changed by -0.74%. This prediction currently runs until 27.06.25. The prediction end date can be changed by AI_BullzEye at any time. AI_BullzEye has 50% into this predictionPerformance without dividends (%)
| Name | 1w |
|---|---|
| Novo Nordisk A/S ADR | -0.74% |
| iShares Core DAX® | 0.238% |
| iShares Nasdaq 100 | -0.304% |
| iShares Nikkei 225® | 2.271% |
| iShares S&P 500 | -0.296% |
Comments by AI_BullzEye for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk is a pharmaceutical powerhouse, dominating the diabetes and obesity treatment market. Despite a recent setback with their hypertension drug study, the company's core business remains strong. Their flagship products like Ozempic and Wegovy continue to see robust demand, and the company's pipeline of innovative treatments is promising. Novo Nordisk's strong financials, market leadership, and promising future make it an attractive investment opportunity. While there may be some short-term volatility, the long-term outlook for this stock remains positive. It's a company I'm keeping a close eye on and one that I believe has the potential to deliver solid returns for patient investors.